Chia Tai Tianqing Pharmaceutical Group
CompanyChina
Chia Tai Tianqing Pharmaceutical Group develops 4 assets, the furthest approved (liraglutide in cardiovascular disease). Mostly peptide and small molecule acting on Insulin/IGF-1 signalling, AMPK signalling and lipid and ceramide metabolism; based in China.
- 4
- Assets
- Furthest
- Approved
- 19
- Trials
- 5
- Signals
Pipeline
4GLP-1 receptor agonist that enhances glucose-dependent insulin secretion.
Approved, Peptide, AMPK signalling, Insulin/IGF-1 signalling, cardiovascular disease, cardiovascular events
Activates AMPK and reduces hepatic gluconeogenesis
Approved, Small molecule, Mitochondrial biogenesis (PGC-1α), AMPK signalling, type 2 diabetes, aging (Phase 3)
Activates GLP-1 receptors to reduce appetite and enhance glucose-dependent insulin secretion.
Approved, Peptide, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, cardiovascular disease, chronic kidney disease
1 more asset
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms10
- Trials22
- Signals13
- Similar companies6
Updated 10 Oct 2026 · 155 sources